Neurocrine Biosciences (NBIX) Cash Flow Statement

Click line-items for a historical chart and %

CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	-96.43M
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	1.01M
Gain on sale of assets	-2.57M
Realized loss on sale of investments
Realized gain on sale of auction rate securities
Cease-use expense	-584K
Deferred revenues
Deferred gain on sale of real estate
Deferred rent
Amortization of premiums on investments	3.15M
Non-cash share-based compensation expense	20.51M
Change in operating assets and liabilities:
Accounts receivable and other assets
Accounts payable and accrued liabilities	878K
Cease-use liability	-239K
Other liabilities
Net cash (used in) provided by operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	-217.14M
Sales and maturities of investments
Deposits and restricted cash	-92K
Proceeds from sales of property and equipment	13K
Purchases of property and equipment	-3.76M
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	2.33M
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents	25.57M
Cash and cash equivalents at beginning of the period	74.2M
Cash and cash equivalents at end of the period	99.76M

Entities mentioned with NBIX